AIM: To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma (DLBCL). METHODS: Sixty patients (median age: 58 years) with histologically confirmed gastric DLBCL treated at four Italian institutions between 2000 and 2007, were included in this analysis. Patients were selected by stage (I-IV, Lugano staging system), European Cooperative Oncology Group performance status (0-2) and treatment strategies. Treatment strategies were chemotherapy alone (group A, n = 30) [scheduled as cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and CHOP-like], and chemotherapy combined with rituximab (group B, n = 30). The primary end point of the study was complete response (CR) rate; the secondary end points were disease-free survival (DFS) at 5 years and overall survival (OS). RESULTS: Median follow-up was 62 mo (range: 31-102 mo). We observed a significant difference between the two groups (A vs B) in terms of CR [76.6% (23/30) vs 100%, P = 0.04) and DFS at 5 years [73.3% (22/30) vs 100%, P = 0.03). To date, 19 group A (63.3%) patients are alive and 11 have died, while all group B patients are alive. No significant differences in toxicity were observed between the two groups. CONCLUSION: Rituximab in combination with chemotherapy improves CR rate, DFS and OS. Further prospective trials are needed to confirm our results.
AIM: To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma (DLBCL). METHODS: Sixty patients (median age: 58 years) with histologically confirmed gastric DLBCL treated at four Italian institutions between 2000 and 2007, were included in this analysis. Patients were selected by stage (I-IV, Lugano staging system), European Cooperative Oncology Group performance status (0-2) and treatment strategies. Treatment strategies were chemotherapy alone (group A, n = 30) [scheduled as cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and CHOP-like], and chemotherapy combined with rituximab (group B, n = 30). The primary end point of the study was complete response (CR) rate; the secondary end points were disease-free survival (DFS) at 5 years and overall survival (OS). RESULTS: Median follow-up was 62 mo (range: 31-102 mo). We observed a significant difference between the two groups (A vs B) in terms of CR [76.6% (23/30) vs 100%, P = 0.04) and DFS at 5 years [73.3% (22/30) vs 100%, P = 0.03). To date, 19 group A (63.3%) patients are alive and 11 have died, while all group B patients are alive. No significant differences in toxicity were observed between the two groups. CONCLUSION:Rituximab in combination with chemotherapy improves CR rate, DFS and OS. Further prospective trials are needed to confirm our results.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: A Neubauer; C Thiede; A Morgner; B Alpen; M Ritter; B Neubauer; T Wündisch; G Ehninger; M Stolte; E Bayerdörffer Journal: J Natl Cancer Inst Date: 1997-09-17 Impact factor: 13.506
Authors: M Raderer; J Valencak; C Osterreicher; J Drach; M Hejna; G Kornek; W Scheithauer; T Brodowicz; A Chott; B Dragosics Journal: Cancer Date: 2000-05-01 Impact factor: 6.860
Authors: M Raderer; A Chott; J Drach; C Montalban; B Dragosics; U Jäger; A Püspök; C Osterreicher; C C Zielinski Journal: Ann Oncol Date: 2002-07 Impact factor: 32.976
Authors: Kucukoner Mehmet; Cihan Sener; Ummugul Uyeturk; Mesut Seker; Didem Tastekin; Onder Tonyali; Ozan Balakan; Omer Kemal Yazici; Zuhat Urakci; Abdurrahman Isikdogan; Nuriye Ozdemir; Ali Inal; Muhammed Ali Kaplan; Ali Suner; Sinan Dal; Dogan Uncu; Mahmut Gumus; Melih Cem Boruban; Berna Oksuzoglu; Orhan Ayyildiz; Mustafa Benekli Journal: Contemp Oncol (Pozn) Date: 2014-07-22